Insights
Recently published articles about Insights
Insights
Update on Current & Emerging Treatments for Negative Symptoms in Schizophrenia
February 21, 2025
In this video, Dr. Kantrowitz provides an in-depth update on current and emerging treatments for the negative symptoms of schizophrenia. He discusses symptom classifications, key clinical trials, and potential...
Insights
The Near-Term Future of Muscarinic Agonists and Modulators for Schizophrenia: M1 and/or M4
February 21, 2025
In this video, Dr. Kantrowitz explores the potential of muscarinic acetylcholine receptor (mACHR) agonists and modulators for schizophrenia treatment, with a focus on M1 and M4 receptors. He reviews...
Insights
What are the Efficacy and Safety of Muscarinic Receptor Modulators in Patients With Schizophrenia?
November 19, 2024
In this video, Dr. Correll examines the therapeutic potential of the muscarinic receptor system in schizophrenia treatment. He discusses how targeting muscarinic receptors may address cognitive and functional impairments,...
Recent JCP Articles on Insights
Original Research
Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial
August 25, 2025
In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.
Original Research
Levomilnacipran, but Not Duloxetine, Inhibits Serotonin and Norepinephrine Reuptake Throughout Its Therapeutic Range
August 25, 2025
Levomilnacipran and duloxetine are both potent serotonin reuptake inhibitors at all therapeutic regimens for MDD. Potent norepinephrine reuptake inhibition can be achieved from initiation with levomilnacipran, in contrast to...
Clinical and Practical Psychopharmacology
The Superiority of Clozapine Over SGAs in Patients With Treatment-Resistant Schizophrenia
August 25, 2025
Clozapine is associated with many adverse effects. Given the findings that olanzapine and risperidone may be as good as clozapine in treatment-resistant schizophrenia (TRS), it may be worth trialing...
